targeting the creb pathway for memory enhancers
Download
Skip this Video
Download Presentation
TARGETING THE CREB PATHWAY FOR MEMORY ENHANCERS

Loading in 2 Seconds...

play fullscreen
1 / 40

TARGETING THE CREB PATHWAY FOR MEMORY ENHANCERS - PowerPoint PPT Presentation


  • 119 Views
  • Uploaded on

TARGETING THE CREB PATHWAY FOR MEMORY ENHANCERS. Tim Tully*, Rusiko Bourtchouladze*, Rod Scott* and John Tallman* Helicon Therapeutics and Cold Spring Harbor Laboratory. How are potential molecular targets for drugs found? How are potential memory drugs discovered and evaluated?

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' TARGETING THE CREB PATHWAY FOR MEMORY ENHANCERS ' - suki


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
targeting the creb pathway for memory enhancers

TARGETING THE CREB PATHWAY FOR MEMORY ENHANCERS

Tim Tully*, Rusiko Bourtchouladze*, Rod Scott* and John Tallman*

Helicon Therapeutics and Cold Spring Harbor Laboratory

slide2
How are potential molecular targets for drugs found?
  • How are potential memory drugs discovered and evaluated?
  • What memory-related diseases are good candidates for CREB-related therapy?
slide3
ACETYLCHOLINE, GLUTAMATE
  • the neurotransmitters acetylcholine and glutamate
  • CHOLINERGIC
  • Pertaining to acetylcholine neurotransmission.
  • CHOLINESTERASE
  • An enzyme that metabolizes the neurotransmitter acetylcholine. Cholinesterase inhibitors lead to increased levels of acetylcholine in the brain.
  • GLUTAMATERGIC
  • Pertaining to glutamate neurotransmission.
slide4
Alzheimer’s disease (AD) pathology
    • associated with a progressive loss of cholinergic neurons
    • historically the pharmaceutical industry has focused on the identification of cholinesterase inhibitors.
  • Marketed AD drugs such as donzepil, rivastigmine and galantamine yield mild improvements
    • effects are variable and not long-lasting
slide5
The biochemical basis of memory.
  • NMDA (N-methyl-D-aspartate)-receptor activation (in mammals) seems to be central to the local, transient biochemical response at the synapse.
  • These transient biochemical responses induce changes in gene expression in the cell nucleus via activation (that is, phosphorylation) of the transcription factor cAMP-response-element-binding protein (CREB).
  • This transcriptional response also depends on NMDA receptor activation.
slide6
Protein kinase A (PKA) and mitogen-activated protein (MAP) kinase signalling pathways play dominant roles in activation.
  • CREB regulates a transcription factor cascade ultimately involved in a growth process that yields synapse-specific structural changes.
  • This process seems to involve microtubule-dependent transport of nascent mRNAs to synaptic regions and local regulation of translation.
slide7
A molecular switch for LTM.
  • Neurogenetic studies have shown CREB to be a key control point for LTM formation.
  • Loss-of-function manipulations of CREB leave learning and STM intact, but impair LTM.
slide8
Gain-of-function manipulations leave learning and STM intact, but enhance LTM formation specifically by reducing the amount of training required to produce maximal LTM.
  • Similar manipulations of CREB also produce changes in synaptic structure and function in several animal models and in various regions of the mammalian brain.
slide9
Molecular targets for drug discovery are those, such as CREB, which act as molecular switches.
  • many genes are involved in stages of memory formation.
  • likely several genes will act as molecular switches and are potential targets for drug screening.
  • combinations of drugs may provide more effective treatments.
two classes of drug targets
Two classes of drug targets
  • a-amino-3-hydroxy-5-methyl-4-isoxazole propionicacid (AMPA) receptors
  • genes in the CREB pathway
slide11
AMPA receptors depolarize postsynaptic membranes in response to glutamate
  • Modulators of AMPA receptors have been developed on the basis of the expectation that they might facilitate NMDA receptor-dependent induction of LTP and, thereby, the acquisition of new memories.
  • Several of these compounds have yielded encouraging results from preclinical animal testing and are now undergoing clinical evaluations.
creb camp genes
CREB / cAMP genes
  • ADENYLYL CYCLASE (AC).
    • An enzyme that synthesizes cAMP from ATP and is involved in intracellular signalling, usually after neurotransmitter activation.
  • PHOSPHODIESTERASE (PDE).
    • An enzyme that hydrolyzes cAMP into AMP.
slide13
Screen for enhancers of CREB signalling.
  • molecular target was discovered to be PHOSPHODIESTERASE4 (PDE4).
assay for creb based memory enhancement
Assay for CREB-based memory enhancement.
  • naive mouse is placed into a novel chamber containing distinct visual, olfactory and tactile cues.
  • mouse receives mild electroshock to its feet.
  • mouse will remember for sometime afterwards that the chamber is dangerous.
  • When placed back into the chamber at a later time, the mouse will freeze, sitting stone still for many seconds, which is its natural response to danger.
  • percentage of time during an observation period that the mouse spends frozen represents a quantitative measure of its memory of a dangerous place.
slide15
normal mouse will learn this task in just one training trial.
  • Tully modified procedure so that more training trials were required to form maximal LTM.
  • By reducing the intensity of footshock, four-day memory retention in normal mice (C57/Bl6) was near zero after one training trial and required five training trials to reach maximum levels.
slide16
In initial experiments with drugs, animals were cannulated and drug (or vehicle alone) was injected directly into the hippocampus shortly before training.
  • Mice received two (submaximal) or five (maximal) training trials.
  • A number of Helicon’s PDE4 inhibitors, and the prototypic PDE4 inhibitor rolipram, enhanced four-day memory after two training trials, but had no effect on memory after five training trials.
slide17
The drugs were then injected intraperitoneally shortly before training to test their ability to penetrate the blood–brain barrier.
  • A number of Helicon’s compounds and rolipram again enhanced four-day memory after two, but not five, training trials.
  • Stated another way, the PDE4 inhibitors enabled memory to form following less than half the normal amount of training.
slide18
Was this effect of the drug specific to one behavioural task, or did it also work with other stimuli and sensory modalities?
  • addressed by evaluating a second behavioural task — object recognition — that relies on a mouse’s natural exploratory behaviour.
slide19
during training for this task, mice are presented with two identical novel objects, which they then explore for some time by orienting toward, smelling and crawling over.
  • presented at a later time with two different objects, one of which was presented previously during training and thus is ‘familiar,’ and the other of which is novel.
slide20
Found that drug-injected mice formed maximal memory with less-than-normal training
  • Thus, PDE4 inhibitors yielded similar effects on memory formation in two distinctly different behavioural tasks,
  • Evidence that their mechanism of action was on the memory process per se rather than on a more nonspecific aspect of a particular behavioural response.
the blood brain barrier
The blood–brain barrier
  • This barrier comprises endothelial cells of brain capillaries.
  • The junctions between these cells are extraordinarily tight and prevent most classes of molecules from moving freely from the blood to the brain.
  • This protective function probably evolved to spare the brain from assault by toxic substances, viruses and peripheral hormones.
slide23
Unfortunately, it also prevents many classes of therapeutic drugs from easily entering the brain.
  • the blood–brain barrier is much reduced in some areas of the brain, such as the hypothalamus where hormonal signals are exchanged with the periphery
slide24
To circumvent the blood–brain barrier for normal metabolism, transport proteins have evolved that actively carry sugars, amino acids and vitamins into the brain.
  • Attempts have been made to use these transport proteins to carry drugs, such as glutamate-receptor agonists and antagonists, but the rate of transport has not been sufficient to deliver adequate doses of drug to the brain.
slide25
The classic way to penetrate the blood–brain barrier is to design small heterocyclic organic molecules.
  • These molecules are generally constructed to have a high degree of lipid solubility (that is, lipophilicity) and a relatively small size (< 500 daltons).
  • Drugs such as rolipram and Helicon’s compounds were designed with this in mind.
slide26
Such design constraints introduce other constraints, however, which can include poor solubility and high affinity for plasma proteins, such as albumin, leaving only a small amount of drug free to equilibrate across the membrane.
slide27
Target specificity (or lack thereof) and high affinity (< 10 nM) are also desirable, but, nonetheless, must be balanced against increased size and the attendant decrease in brain penetrance.
  • CNS drug design constitutes a series of compromises to balance these various drug properties.
the p glycoprotein problem
The P-glycoprotein problem
  • Achieving the optimal design to penetrate the blood–brain barrier does not automatically ensure that therapeutic levels of drug will reach the brain.
  • There are powerful mechanisms in the more permeable areas of the brain, such as the choroid plexus, that actively pump noxious substances out of the brain.
  • One of these pumps, P-glycoprotein, was first recognized as the multi-drug resistance factor in cancer chemotherapy
unique side effects for central nervous system drugs
Unique side effects for central nervous system drugs
  • Molecular targets for central nervous system (CNS) drugs are usually involved in normal neuronal functions.
  • Moreover, they often function in different types of neurons (excitatory versus inhibitory, for instance).
  • Consequently, CNS drugs can have side effects that are specific to various brain functions.
excitotoxicity
Excitotoxicity
  • Some CNS drugs can have excitatory effects on neuronal activity, which induce seizures. These may be a direct effect of the drug or result from indirect activation of excitatory transmitter (glutamate) release.
depressant
Depressant
  • CNS drugs can have inhibitory effects on neuronal function that promote drowsiness and even unconsciousness and death. These activities can result from membrane stabilizing (or local anaesthetic) actions or from interaction with inhibitory transmitters, such as GABA (-aminobutyric acid).
emesis
Emesis
  • CNS drugs with specific dopamine receptor activation can cause emesis and nausea.
weight gain
Weight gain
  • Some nonselective antipsychotic medications, such as olanzepine, cause weight gain.
  • Receptor knockouts in rodents have suggested that the 5-HTreceptor may be involved.
sexual dysfunction
Sexual dysfunction
  • Selective serotonin re-uptake inhibitors (SSRIs) are known to produce sexual dysfunction.
  • Sexual dysfunction has not been reported as frequently with other classes of re-uptake blocker (noradrenaline and dopamine) and with monoamine oxidase inhibitors.
  • All can function as antidepressants.
stroke rehabilitation
Stroke rehabilitation
  • The extensive, repetitive training that stroke patients undergo after recovering from the acute ischaemic trauma is likely to invoke synaptic plasticity to ‘remodel’ neuronal connections surrounding the damaged region, thereby recovering a certain degree of lost function65–68.
  • Co-administration of a CREB-based memory enhancer and training might yield more rapid functional recovery (that is, less training will be required to regain performance).
alzheimer s disease
Alzheimer’s disease
  • CREB dependent gene transcription apparently is not involved in the pathology (neurodegeneration) associated with AD.
  • Moreover, CREB-dependent memory formation involves the normal chemistry of healthy neurons.
  • Hence, the efficacy of CREB-dependent memory enhancers might be expected to be lowest when treating patients with moderate to severe AD.
treatment of early stage ad patients
Treatment of early-stage AD patients
  • Animal models of ß-amyloid pathology show that memory defects develop well before any signs of neurodegeneration.
  • As neurodegeneration proceeds, however, individual neurons die more or less randomly within particular brain regions.
  • A kind of mini-stroke.
slide39
Psychological studies of human amnesiacs, mnemonists and people with exceptional or normal memory, have demonstrated that memory is a distinctive cognitive function that can be measured and studied independently of other cognitive abilities that humans possess (for example, reasoning, planning, abstracting, sequencing, language) or brain functions such as perception, motivation, emotion or motor activities.
slide40
H.M.
  • The patient known as H.M., who has arguably become the single most studied and quoted patient in the history of medical research, developed a severe memory deficit following surgical removal of portions of his medial temporal lobes (including the hippocampus).
  • H.M.\'s severe memory loss, however, was contrasted by intact cognitive functions such as perceptual learning, language and reasoning.
ad